| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement D Moher, A Liberati, J Tetzlaff, DG Altman, t PRISMA Group* Annals of internal medicine 151 (4), 264-269, 2009 | 148758 | 2009 |
| The PRISMA 2020 statement: an updated guideline for reporting systematic reviews MJ Page, JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow, ... Bmj 372, 2021 | 56428 | 2021 |
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration A Liberati, DG Altman, J Tetzlaff, C Mulrow, PC Gøtzsche, JPA Ioannidis, ... Annals of internal medicine 151 (4), W-65-W-94, 2009 | 50288 | 2009 |
| SPIRIT 2013 statement: defining standard protocol items for clinical trials AW Chan, JM Tetzlaff, DG Altman, A Laupacis, PC Gøtzsche, ... Annals of internal medicine 158 (3), 200-207, 2013 | 5856 | 2013 |
| Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials JAC Sterne, AJ Sutton, JPA Ioannidis, N Terrin, DR Jones, J Lau, ... Bmj 343, 2011 | 5772 | 2011 |
| SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials AW Chan, JM Tetzlaff, PC Gøtzsche, DG Altman, H Mann, JA Berlin, ... Bmj 346, 2013 | 4785 | 2013 |
| The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372: n71 MJ Page, JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow, ... | 3503* | 2021 |
| The PRISMA, et al. statement: an updated guideline for reporting systematic reviews MJ Page, JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow, ... Bmj 2021 (372), 71, 2020 | 2581 | 2020 |
| Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement MJ Page, JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow, ... Journal of clinical epidemiology 134, 103-112, 2021 | 1473 | 2021 |
| Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas MJ Page, JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow, ... Revista española de cardiología 74 (9), 790-799, 2021 | 1304 | 2021 |
| Epidemiology and reporting characteristics of systematic reviews D Moher, J Tetzlaff, AC Tricco, M Sampson, DG Altman PLoS medicine 4 (3), e78, 2007 | 1065 | 2007 |
| Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study MJ Page, L Shamseer, DG Altman, J Tetzlaff, M Sampson, AC Tricco, ... PLoS medicine 13 (5), e1002028, 2016 | 680 | 2016 |
| The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration A Liberati, DG Altman, J Tetzlaff, C Mulrow, PC Gøtzsche, JPA Ioannidis PLoS medicine 6 (7), 1-28, 2009 | 618 | 2009 |
| Methods of systematic reviews and meta-analysis preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement D Moher, A Liberati, J Tetzlaff, DG Altman J Clin Epidemiol 62 (10), 1006-12, 2009 | 536 | 2009 |
| The PRISMA 2020 statement: an updated guideline for reporting systematic reviews JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow, ... Bmj 372 (71), 1-9, 2021 | 521 | 2021 |
| PRISMA Group*, T.(2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement D Moher, A Liberati, J Tetzlaff, DG Altman Annals of internal medicine 151 (4), 264-269, 0 | 455 | |
| The PRISMA Group PRISMA 2009 flow diagram D Moher, A Liberati, J Tetzlaff, DG Altman PLoS Med 6 (7), e1000097, 2009 | 438 | 2009 |
| PA, Clarke M., Devereaux PJ, Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions … A Liberati, DG Altman, J Tetzlaff, C Mulrow, PC Gotzsche, J Ioannidis Bmj 339, b2700-b2700, 2009 | 371 | 2009 |
| Group PRISMA. 2009.“ D Moher, A Liberati, J Tetzlaff, D Altman Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The …, 0 | 340* | |
| SPIRIT 2013: new guidance for content of clinical trial protocols AW Chan, JM Tetzlaff, DG Altman, K Dickersin, D Moher The Lancet 381 (9861), 91-92, 2013 | 306 | 2013 |
